Cargando…
Correction: A real-world evaluation of radium-223 in combination with abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancer
Autores principales: | Kim, Stephanie I., Szeto, Andy H., Morgan, Katherine P., Brower, Blaine, Dunn, Mary W., Khandani, Amir H., Godley, Paul A., Rose, Tracy L., Basch, Ethan M., Milowsky, Matthew I., Whang, Young E, Crona, Daniel J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8719726/ https://www.ncbi.nlm.nih.gov/pubmed/34972194 http://dx.doi.org/10.1371/journal.pone.0262326 |
Ejemplares similares
-
A real-world evaluation of radium-223 in combination with abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancer
por: Kim, Stephanie I., et al.
Publicado: (2021) -
Association of Chemotherapy, Enzalutamide, Abiraterone, and Radium 223 With Cognitive Function in Older Men With Metastatic Castration-Resistant Prostate Cancer
por: Alibhai, Shabbir M. H., et al.
Publicado: (2021) -
Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer
por: Shore, Neal, et al.
Publicado: (2020) -
Prognosis and safety of radium‐223 with concurrent abiraterone acetate or enzalutamide use for metastatic castration‐resistant prostate cancer: Real‐world data of Japanese patients
por: Miyoshi, Yasuhide, et al.
Publicado: (2020) -
Enzalutamide Prior to Radium-223 Is Associated with Better Overall Survival in Metastatic Castration-Resistant Prostate Cancer Patients Compared to Abiraterone—A Retrospective Study
por: Chen, Hao Xiang, et al.
Publicado: (2023)